Table 4 Relative sensitivity, specificity and PPV of different tests for the detection of high-grade disease based on 19 CIN3+ cases and 40 CIN2+ cases
From: Comparing the performance of six human papillomavirus tests in a screening population
Test | Sensitivity (95% CI) | Specificity (95% CI) | PPV (%,all) (95% CI) | PPV (%,only for those referred for colposcopy) (95% CI) |
|---|---|---|---|---|
BD HPV | ||||
CIN3+ | 100.0 (82.4–100.0) | 2.0 (1.2–3.0) | 16.5 (10.3–24.6) | |
CIN2+ | 97.5 (86.8–99.9) | 84.3 (83.3–85.2) | 4.0 (2.9–5.5) | 33.9 (25.3–43.3) |
Roche Cobas | ||||
CIN3+ | 100.0 (82.4–100.0) | 2.0 (1.2–3.1) | 16.7 (10.3–24.8) | |
CIN2+ | 97.5 (86.8–99.9) | 84.5 (83.6–85.4) | 4.1 (2.9–5.5) | 34.2 (25.6–43.7) |
Qiagen Hybrid Capture 2 | ||||
CIN3+ | 100.0 (82.4–100.0) | 2.1 (1.3–3.3) | 16.0 (9.9–23.8) | |
CIN2+ | 97.5 (86.8–99.9) | 85.4 (84.5–86.3) | 4.3 (3.1–5.8) | 32.8 (24.4–42.0) |
Abbott RealTi m e High Risk HPV | ||||
CIN3+ | 94.7 (74.0–99.9) | 2.2 (1.3–3.5) | 16.1 (9.8–24.2) | |
CIN2+ | 95.0 (83.1–99.4) | 87.2 (86.3–88.0) | 4.7 (3.4–6.5) | 33.9 (25.3–43.5) |
Gen-Probe APTIMA | ||||
CIN3+ | 100.0 (82.4–100.0) | 3.1 (1.9–4.7) | 17.4 (10.8–25.9) | |
CIN2+ | 97.5 (86.8–99.9) | 90.2 (89.5–91.0) | 6.3 (4.5–8.5) | 35.8 (26.8–45.5) |
NorChip PreTect HPV-Proofer a | ||||
CIN3+ | 68.8 (41.3–89.0) | 3.7 (1.9–6.5) | 20.0 (10.4–33.0) | |
CIN2+ | 71.4 (53.7–85.4) | 95.2 (94.7–95.8) | 8.4 (5.5–12.2) | 45.5 (32.0–59.4) |
